• Better transplant-free survival for colectomy with ileostomy in PSC patients

    Primary sclerosing cholangitis patients who received colectomy with ileostomy had a higher survival chance without liver transplant than those without surgery.

  • Intravenous N-acetylcysteine performs well in hospitalised patients

    I.V. N-acetylcysteine demonstrated mucolytic and expectorant efficacy in hospitalised patients with respiratory diseases and abnormal mucus secretion.

  • Head-to-head: lung volume reduction surgery vs endobronchial valves

    LVRS was not highly superior to bronchoscopic lung volume reduction with valve placement for emphysema patients eligible for both treatment options.

  • Mirikizumab improves histologic and endoscopic signs of inflammation in UC

    Therapy with mirikizumab leads to a higher percentage of patients achieving resolution of active colonic inflammation with absence of neutrophils at induction.

  • Digitally enhanced therapy lowers treatment burden and costs in severe asthma

    Burden was greatly reduced with a digital tool set that informed evidence-based care with data on medication adherence, inhaler technique, and peak flow.

  • Durable effect of endobronchial valves in severe emphysema

    Durable benefits for endobronchial one-way SVS valves over only medical management for hyperinflation in severe heterogenous emphysema.

  • Antifibrotic therapy may slow down FVC decline in RAILD

    Pirfenidone in rheumatoid arthritis-associated interstitial lung disease failed its primary endpoint, but may benefit RAILD patients with usual interstitial pneumonia.

  • Cirrhotic patients are in urgent need of a third SARS-COV-2 vaccine

    Cirrhotic patients had insufficient T cell reactivity after 2 mRNA vaccine doses. But a booster and a natural infection led to higher antibody levels in this group.

  • Favipiravir may help younger patients with COVID-19 recover

    Early intervention with favipiravir did not improve clinical outcomes for hospitalised patients, but the agent may induce health benefits for patients under 60 years of age.

  • Deep learning predicts relapse and mutational profile risks in GIST

    Deep learning from digitalised haematoxylin and eosin-stained whole-tumour slide images outperformed classical Miettinen relapse risks prediction.

  • Brensocatib fails in severe COVID-19

    Brensocatib did not improve the health status of patients with severe COVID-19. Active neutrophil elastase was decreased in treated patients without benefit.

  • Do digital tools improve physical activity in COPD?

    Compared with usual care, a web-based, self-management support tool improved physical activity levels of COPD patients, suggest preliminary trial results.

  • COPD medication not effective in symptomatic smokers with preserved spirometry

    Long-acting bronchodilators do not appear to improve respiratory symptoms in symptomatic tobacco-exposed individuals, Rethinc trial data suggests.

  • Inhaled corticosteroids helped preterms with decreased lung function

    Corticosteroids improved lung function for premature children. A study suggests that bronchodilator responsiveness helps screening patients for this approach.

  • Encouraging results of nintedanib in children with fibrosing ILD

    With an acceptable safety profile and promising efficacy data, nintedanib is a potential candidate for pediatric fibrosing interstitial lung disease treatment.

  • Antibiotics are harmful in severe RSV bronchiolitis

    Azithromycin should be avoided in early-life, severe rRSV bronchiolitis due to association with higher recurrent wheezing risks. Other antibiotics may have the same harmful effect.

  • High responses to neoadjuvant immune checkpoint inhibition in local dMMR colon cancer

    Treatment with nivolumab/ipilimumab for 4 weeks achieved a major pathological response in 95% of patients with stage III dMMR colon cancer.

  • Mepolizumab beneficial for patients with severe eosinophilic asthma

    In patients with SEA, continued reductions in clinically significant exacerbations were reported with mepolizumab administration after 2 years of follow-up.

  • Icenticaftor achieves results on top of triple inhalation therapy in COPD

    After 24 weeks, the use of icenticaftor on top of triple inhalation therapy resulted in a clear dose-response on 5 endpoints in patients with COPD and chronic bronchitis.

  • Digital asthma intervention: Better health, lower costs

    A pharmacy-supported digital programme improved therapy and technique adherence for uncontrolled asthma patients, leading to better asthma control.

  • 1 |
  • 2 |
  • 3 |
  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |
  • 10 |
  • 11 |